WO2009099204A1 - アビバクテリウム・パラガリナラム抗体の検出方法およびキット - Google Patents
アビバクテリウム・パラガリナラム抗体の検出方法およびキット Download PDFInfo
- Publication number
- WO2009099204A1 WO2009099204A1 PCT/JP2009/052091 JP2009052091W WO2009099204A1 WO 2009099204 A1 WO2009099204 A1 WO 2009099204A1 JP 2009052091 W JP2009052091 W JP 2009052091W WO 2009099204 A1 WO2009099204 A1 WO 2009099204A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- amino acid
- acid sequence
- seq
- sequence represented
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 57
- 238000001514 detection method Methods 0.000 title claims abstract description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 150
- 238000002965 ELISA Methods 0.000 claims abstract description 27
- 239000000427 antigen Substances 0.000 claims abstract description 24
- 102000036639 antigens Human genes 0.000 claims abstract description 24
- 108091007433 antigens Proteins 0.000 claims abstract description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 57
- 150000001413 amino acids Chemical class 0.000 claims description 120
- 241000287828 Gallus gallus Species 0.000 claims description 59
- 108010091748 peptide A Proteins 0.000 claims description 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 50
- 101800005149 Peptide B Proteins 0.000 claims description 34
- 210000002966 serum Anatomy 0.000 claims description 32
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 27
- 238000005259 measurement Methods 0.000 claims description 24
- 238000000691 measurement method Methods 0.000 claims description 8
- 238000001262 western blot Methods 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 abstract description 48
- 101710116435 Outer membrane protein Proteins 0.000 abstract description 5
- 241000606767 Avibacterium paragallinarum Species 0.000 abstract description 3
- 108010071023 Bacterial Outer Membrane Proteins Proteins 0.000 abstract 1
- 235000013330 chicken meat Nutrition 0.000 description 55
- 108020004414 DNA Proteins 0.000 description 35
- 229920001184 polypeptide Polymers 0.000 description 34
- 239000012634 fragment Substances 0.000 description 32
- 229960005486 vaccine Drugs 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 14
- 230000002458 infectious effect Effects 0.000 description 12
- 206010039083 rhinitis Diseases 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 101150090724 3 gene Proteins 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108010011042 Envoplakin Proteins 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102100027253 Envoplakin Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000002788 anti-peptide Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010029719 Nonspecific reaction Diseases 0.000 description 2
- 101710194807 Protective antigen Proteins 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 206010042682 Swelling face Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000003617 indole-3-acetic acid Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101100007857 Bacillus subtilis (strain 168) cspB gene Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 101150110403 cspA gene Proteins 0.000 description 1
- 101150068339 cspLA gene Proteins 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- -1 tripeptides Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/14—Disorders of ear, nose or throat
Definitions
- the present invention relates to a detection method and a detection kit for an Abibacterium paragalinarum antibody.
- Avibacterium paragallinarum hereinafter also referred to as A.pg, formerly known as Hemophilus paragallinarum
- A.pg Avibacterium paragallinarum
- C type outer membrane protein hereinafter, an antibody induced by “HMT p210 polypeptide”
- HMT p210 polypeptide an antibody induced by “HMT p210 polypeptide”
- the present invention relates to a method for detecting an Abibacterium paragalinarum antibody, and a detection kit used in the method.
- Peptides are called by names such as dipeptides, tripeptides, oligopeptides and polypeptides depending on the number of amino acid residues constituting them. In the present invention, these are simply defined as peptides without distinction.
- chicken infectious coryza An important respiratory organ disease of chickens is chicken infectious coryza which develops due to A.pg infection. Chickens that develop chicken infectious coryza have nasal discharge, facial swelling or lacrimation as the main symptoms. Chicken infectious coryza has a large economic loss because it causes a decrease in the breeding rate of chickens, a delay in the start of spawning, a decrease in the spawning rate or a halt of spawning.
- Page et al. Classified A.pg into three types, A, B and C (Non-patent Document 1), and Sawata et al. Classified into two types, 1-type and 2-type (Non-patent Document 2). . Thereafter, it was reported by Kume et al. That Page type A corresponds to type 1 of Sawata et al. And Page type C corresponds to type 2 of Sawata et al. (Non-patent Documents 3 and 4).
- A.pg type A type 1 bacteria
- A.pg-A type bacteria type C
- A.pg-C type type 2 bacteria
- a gene that encodes an infection protective antigen is cloned by a component vaccine or genetic recombination technology that removes only an infection protective antigen, that is, an effective component from the bacterial cells or culture supernatant, and uses the vaccine, Genes that express genes in bacteria, yeast, animal cells, plant cells, insect cells, etc., purify the expression products expressed in large quantities, and use these as vaccines for recombinant vaccines, or for genes that encode protective antigens as viral vectors Development of vector vaccines inserted into the
- Tokunaga et al. Induced the production of hemagglutination-inhibiting antibody (HI antibody) from the culture solution of A. pg-A type bacteria, and protected the A. pg-A type A
- HI antibody hemagglutination-inhibiting antibody
- Patent Document 1 A polypeptide having a molecular weight of about 130 kDa derived from a bacterium was successfully purified.
- Patent Document 1 the present inventors have found that the recombinant protein cloned from a DNA fragment encoding the 130 kDa polypeptide and expressed in Escherichia coli protects against infection of chicken infectious coryza caused by Abibacterium paragalinarum type A.
- an HMT-p210 gene encoding an A type HMT-p210 polypeptide (cell outer membrane protein having hemagglutination activity) consisting of 2,042 amino acids was identified.
- a DNA fragment that hybridizes with the DNA fragment was also cloned from type C bacteria to obtain a type C HMT ⁇ p210 gene derived from type C bacteria (Patent Document 2).
- region 1 the region of about 3.4 kbp on the 5 ′ side
- region 3 3′-side approximately 1.2 kbp region
- region 2 approximately 1.5 kbp region
- Noro et al. Have reported that the HMTp210 gene discovered by Tokunaga et al. Is important as a target region for type-specific vaccines. Noro et al. Immunized chickens with a peptide encoded by a 4,801 bp to 5,157 bp DNA fragment, which is part of the HMT p210 gene encoding the A.pg-A type HMT p210 polypeptide. It has been reported that HI antibody is induced against A. pg-A type bacteria and has a vaccine effect (Patent Document 3).
- HA hemagglutinin
- HI test hemagglutination inhibition test using an anti-HA antibody
- B-ELISA blocking ELISA
- a type-specific monoclonal antibody as a serodiagnosis method replacing the HI test
- Non-patent Document 6 B-ELISA is an ELISA method that competitively detects antibodies in serum using monoclonal antibodies that react with each serotype as antigens obtained by ultrasonically disrupting type A or C cells. . This method has the advantage that it has higher sensitivity than the HI test and can handle many samples.
- the B-ELISA is a system that detects an antibody against only an antigen epitope recognized by one monoclonal antibody in each serotype.
- An object of the present invention is to provide an antibody detection method capable of distinguishing antibodies against A and P type A and C type bacteria.
- the present invention provides a method for detecting an antibody characterized by using a recombinant antigen peptide capable of distinguishing antibodies against A. pg A-type bacteria and C-type bacteria. More specifically, the present invention provides an antibody detection method using a recombinant antigen peptide containing an amino acid sequence in a region having low homology between the outer membrane proteins of A. pg A and B type bacteria. .
- the present inventors have found that the p210 polypeptide encoded by the HMTHp210 gene, which is important as a vaccine antigen, is located at a distant position in the amino acid sequence of region 2.
- a homologous amino acid sequence is included between pg-A and A.pg-C (amino acids 243 to 273 of A.pg-A described in SEQ ID NO: 1 and SEQ ID NO: 2)
- amino acids 243 to 273 of A.pg-A described in SEQ ID NO: 1 and SEQ ID NO: 2 Of the 38th to 68th amino acid sequences of the A. pg-C type bacterium of A. pg-C, 29 amino acids matched (see FIG. 3), and the amino acid sequence was found to form an epitope.
- the inventors of the present application include an amino acid sequence having high homology between A.pg-A and A.pg-C type bacteria in part of the C-terminal region of region 2 defined by Tokunaga et al. I found out. Therefore, in each of the HMTp210 polypeptides of A.pg-A type bacteria and A.pg-C type bacteria, peptides that do not contain the above two homologous amino acid sequences are prepared, and the obtained peptides are used to fix to the microplate. Antibody measurement by phased ELISA was performed.
- the present invention is as follows.
- a method for detecting an Abibacterium paragalinarum antibody comprising an antibody measurement method in which a specimen is reacted with at least one antigen of peptide A or B below.
- Peptide A A peptide which is a part of the amino acid sequence represented by SEQ ID NO: 1 and which comprises a peptide chain of 6 amino acids or more and does not contain the amino acid sequences 243 to 273 of the amino acid sequence represented by SEQ ID NO: 1.
- Peptide B A peptide that is a part of the amino acid sequence represented by SEQ ID NO: 2, comprises a peptide chain of 6 amino acids or more, and does not contain the 38th to 68th amino acid sequences of the amino acid sequence represented by SEQ ID NO: 2.
- Peptide B A part of the amino acid sequence represented by SEQ ID NO: 2, comprising the amino acid sequence of positions 69 to 452 of the amino acid sequence represented by SEQ ID NO: 2, and the 38th to 68th positions of the amino acid sequence represented by SEQ ID NO: 2 A peptide that does not contain an amino acid sequence.
- Peptide A A peptide comprising the 8th to 236th amino acid sequence of the amino acid sequence represented by SEQ ID NO: 1.
- Peptide B A peptide consisting of the amino acid sequence of positions 69 to 452 of the amino acid sequence represented by SEQ ID NO: 2.
- peptide A is the following peptide chain.
- Peptide A A part of the amino acid sequence represented by SEQ ID NO: 1, comprising the amino acid sequence from 274 to 445th of the amino acid sequence represented by SEQ ID NO: 1, and the 243rd to 273th of the amino acid sequence represented by SEQ ID NO: 1 A peptide that does not contain an amino acid sequence.
- Peptide A A peptide comprising the amino acid sequence at positions 274 to 445 in the amino acid sequence represented by SEQ ID NO: 1.
- peptide A or B is a peptide having an amino acid sequence in which one or several amino acid residues are deleted, added, or substituted
- the detection method described The detection method described.
- Peptide A A peptide which is a part of the amino acid sequence represented by SEQ ID NO: 1 and which comprises a peptide chain of 6 amino acids or more and does not contain the amino acid sequences 243 to 273 of the amino acid sequence represented by SEQ ID NO: 1.
- Peptide B A peptide that is a part of the amino acid sequence represented by SEQ ID NO: 2, comprises a peptide chain of 6 amino acids or more, and does not contain the 38th to 68th amino acid sequences of the amino acid sequence represented by SEQ ID NO: 2.
- Peptide B A part of the amino acid sequence represented by SEQ ID NO: 2, comprising the amino acid sequence of positions 69 to 452 of the amino acid sequence represented by SEQ ID NO: 2, and the 38th to 68th positions of the amino acid sequence represented by SEQ ID NO: 2 A peptide that does not contain an amino acid sequence.
- Peptide A A peptide comprising the 8th to 236th amino acid sequence of the amino acid sequence represented by SEQ ID NO: 1.
- Peptide B A peptide consisting of the amino acid sequence of positions 69 to 452 of the amino acid sequence represented by SEQ ID NO: 2.
- a method and kit for detecting an Abibacterium paragalinarum antibody are provided. Since the peptides derived from A.pg-A and A.pg-C used in the present invention do not contain homologous amino acid sequences, for example, vaccines derived from A.pg-A and A Each antibody specifically binds to an antibody induced by a vaccine derived from type pg-C. Therefore, the detection method and kit of the present invention are not limited to the case where each vaccine is administered alone to a chicken, but also when a mixed vaccine is administered, the antibody titer against each bacterium present in chicken serum is determined. Each can be identified and measured.
- the present invention as a result of using the purified recombinant antigen, it is possible to immobilize a higher concentration of antigen as compared with the conventional technique using a disrupted product of A.pg cells. It is considered possible to construct an antibody measurement system with higher detection sensitivity.
- the antibody detection method of the present invention since the antibody detection method of the present invention has the ability to identify the serotype of A.pg in the antigenic peptide, it is simpler than the B-ELISA using a type-specific monoclonal antibody, and has a viewpoint of antigenic mutation of bacteria. Can detect an antibody against A.pg more reliably.
- the detection method of the present invention can identify not only chicken serum after vaccine administration but also antibodies in A.pg infected chicken serum.
- FIG. 1 is a drawing showing the positional relationship between HMTp210 polypeptide and fragments thereof and each fragment.
- the black part shows the homologous sequence in the region 2, and the shaded part shows the C-terminal homologous region of the region 2.
- the amino acid sequence numbers shown in the figure correspond to the amino acid sequence numbers disclosed in SEQ ID NO: 1 (type A) and SEQ ID NO: 5 (type C) in Patent Document 2.
- FIG. 2 is a drawing showing the results of SDS-PAGE of each polypeptide purified from E. coli: M: marker, lane 1: P-A ⁇ 6b-1b, lane 2: P-C ⁇ 6b-1b FIG.
- FIG. 3 is a drawing showing the homologous amino acid sequence and its position in the non-homologous region of the amino acid sequence encoded by the HMT p210 gene.
- the amino acid sequence numbers shown in the figure correspond to the amino acid sequence numbers disclosed in SEQ ID NO: 1 (type A) and SEQ ID NO: 5 (type C) in Patent Document 2.
- FIG. 4 is a drawing showing the correlation between the ELISA value using the polypeptide P-A ⁇ 6b-2 # in the serum before type A bacterial challenge as an antigen and the onset protection after type A bacterial challenge.
- ⁇ represents a chicken that did not develop
- ⁇ represents a chicken that developed.
- FIG. 5 is a drawing showing the correlation between the ELISA value using the polypeptide P-C ⁇ 6b-1b in the serum before C-type bacteria attack as an antigen and the onset protection after C-type bacteria challenge.
- ⁇ represents a chicken that did not develop
- ⁇ represents a chicken that developed.
- the present invention relates to a homologous amino acid sequence between A.pg-A type bacteria and A.pg-C type bacteria that are slightly present in the non-homologous region in the amino acid sequence encoded by the HMTpgp210 gene derived from A.pg. It is characterized by a method and a kit for detecting an Abibacterium paragalinarum antibody by an antibody assay using a peptide from which the peptide has been removed as an antigen.
- the non-homologous region of the amino acid sequence encoded by the HMT p210 gene derived from A.pg-A and / or A.pg-C as an antigen Part of it is used.
- the non-homologous region is an amino acid sequence encoded by a DNA region of about 3.4 kbp on the 5 ′ side (region 1) and an amino acid sequence encoded by a DNA region of about 1.2 kbp on the 3 ′ side (region 3).
- nucleotide sequences corresponding to the non-homologous regions of the HMT p210 gene of the three A-type strains (221 strain, O53 strain and W strain) isolated from A.pg-infected chickens are completely identical between the O53 strain and the W strain. Only one base is mutated between the strain and 221 strains.
- nucleotide sequence of the same region between 3 strains of C-type bacteria 53-47 strain, modest strain and NK-1 strain
- the A.pg-1.3 gene and a DNA fragment containing it can be obtained according to the following method.
- a medium appropriately containing polypeptone, glucose, casamino acid, sodium glutamate, yeast extract, sodium chloride, chicken water, ⁇ NAD, chicken serum and the like is used.
- chicken serum-added chicken broth medium 1000 mL medium, polypeptone S 5 g, casamino acid 1 g, sodium chloride 5 g, sodium L-glutamate 5 g, glucose koji 1 g, yeast extract for growth of small and medium-sized cells.
- the culture conditions are usually set in the range of a temperature of 37 ° C. and a period of 16 to 24 hours, but may be appropriately adjusted according to the purpose of use, the culture form, the amount of planted bacteria, the medium scale, and the like.
- the bacterial cells in the culture solution are recovered in the sediment by centrifugation (8,000 rpm, 20 minutes).
- the HMT p210 gene is derived from total RNA, mRNA or genomic DNA extracted from bacterial cells as a starting material.
- General gene recombination technology described by Sambrook et al. (Molecular Cloning, A Laboratory Manual Second Edition. Cold Spring Harbor Laboratory Press , NY, 1989). In practice, commercially available kits are used.
- reagents such as TRIzol reagent (Invitrogen), ISOGEN (Nippon Gene), StrataPrep Total RNA Purification Kit (Toyobo), for extraction of chromosomal DNA, Sepagene kit (Sanko Junyaku), ISOPLANT (Wako Pure Chemicals), mRNA purification kits such as mRNA Purification Kit (Amersham Biosciences), Poly (A) Quick mRNA Isolation Kit (Toyobo), mRNA Separator Kit (Clontech), and conversion to cDNA SuperScript plasmid system for cDNA synthesis and plasmid cloning (Invitrogen), cDNA Synthesis Kit (Takara Shuzo), SMART PCR cDNA Synthesis & Library Construction Kits (Clontech), Directionary cDNA Library Construction systems (Novagen), GeneAmp GeneAmp Applied Biosystems).
- TRIzol reagent Invitrogen
- ISOGEN Nippon Gene
- chromosomal DNA is extracted from the cells collected by centrifugation using a Sepagene kit (Sanko Junyaku), etc., and cleaved with an appropriate restriction enzyme (preferably EcoRI is used). And inserted into a commercially available cloning vector (for example, ⁇ gt11; New England Biolabs (NEB)) to prepare a DNA library.
- DNA fragments of various sizes are amplified by the PCR method using LA Taq (Takara Bio Inc.) using the obtained DNA fragment as a template (template) according to the attached protocol.
- Primers used for PCR are designed based on the nucleotide sequence of HMT p210 gene derived from A.pg-A type bacteria and A.pg-C type bacteria disclosed by Tokunaga et al. (Patent Document 1). PCR primers can be easily obtained by requesting a DNA synthesis contract organization (for example, Sigma Genosys Japan). At this time, base sequences of appropriate restriction enzyme cleavage sites are added to the 5 ′ end of the upstream Primer and the 5 ′ end of the downstream Primer.
- the PCR amplification product is cloned into a gene cloning vector, pCR-XL-TOPO (Invitrogen Corporation), and a plasmid pCRDNT into which various DNA fragments are inserted is obtained.
- the base sequence of the obtained DNA fragment is once cloned into pBluescript II SK + (Stratagene) or pCR2.1-TOPO (Invitrogen) and then determined by a DNA sequencer (ABI Prism 377 Applied Biosystems).
- a peptide with a partial amino acid mutation can also be used as an antigen in the antibody measurement method of the present invention.
- a mutation is introduced into a specific amino acid in a peptide, it is common to use a cytodirected mutagenesis method in which a mutation is introduced into the base sequence of a DNA fragment encoding the peptide.
- Takara's Site-Directed Mutagenesis System (Mutan-Super Express Km, Mutan-Express Km, Mutan-K, etc.), Stratagene QuickChange Multi-Site-Directed Mutagenesis Kit, and QuickChange XL XL Site- A commercially available kit such as Directed ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ Mutagenesis Kit or Invitrogen's GeneTailor Site-Directed Mutagenesis System is used according to the attached protocol.
- Each DNA fragment is expressed by incorporating the thus obtained DNA fragment into an appropriate expression vector and introducing it into a host.
- an appropriate expression vector for example, pQE30 (manufactured by Qiagen) or pET22b (manufactured by Novagen or Takara Bio Inc.) may be used as an expression vector, and may be appropriately selected.
- Bacteria, yeast, animal cells, plant cells, insect cells and the like are commonly used for the expression of foreign proteins and peptides, but may be selected according to the purpose of use.
- a known method may be used when transforming a host cell.
- a calcium phosphate method for example, a calcium phosphate method, a DEAE dextran method, a method using lipofectin-based liposomes, a protoplast polyethylene glycol fusion method, an electroporation method, and the like can be used, and an appropriate method may be selected depending on the host cell to be used.
- Escherichia coli that can be expressed in a large amount is used.
- Various expression vectors having trp promoter, T7 promoter, cspA promoter, and the like have been developed and marketed for E. coli expression, and may be appropriately selected from these.
- E. coli such as BL21, HMS174, DH5 ⁇ , HB101, JM109 or the like is selected as a host in accordance with the expression vector. Transformation of E. coli can be performed using a commercially available competent cell according to the attached method. In this way, recombinant E. coli that produces the desired polypeptide is obtained.
- Medium used for culturing E. coli eg, LB, SOC, SOB, etc.
- reagent used for selection of transformants eg, ampicillin, etc.
- reagent used for expression induction eg, indole acetic acid (IAA)
- IPTG isopropylthio- ⁇ -D-galactoside
- the pH of the medium is used in a range suitable for the growth of E. coli (pH 6-8).
- a surfactant for example, Triton X100
- a chelating agent for example, EDTA
- lysozyme and the like may be appropriately added to distilled water.
- a certain amount of the expression product collected in the supernatant and sediment is subjected to SDS-polyacrylamide gel electrophoresis and stained with Coomassie Brilliant Blue, and then the expression of the target product is confirmed from the molecular size and stained image.
- a method based on an antigen-antibody reaction such as ELISA, Western blot, or dot blot may be used for confirmation (or detection) of the target. Both are general methods for detecting foreign proteins and polypeptides expressed in E. coli, and may be appropriately selected depending on the purpose.
- purification methods generally used in protein chemistry, such as centrifugation, salting out, ultrafiltration, isoelectric precipitation, electrophoresis, ion exchange
- a combination of methods such as chromatography, gel filtration chromatography, affinity chromatography, hydrophobic chromatography, and hydroxyapatite chromatography is used.
- the amount of the obtained protein or polypeptide is measured using a protein measuring reagent such as BCA-Protein-Assay-Reagent-Kit (Pierce-Biotechnology, Inc) or Protein-Assay-Kit (BIO-RAD, Inc).
- the target product may be expressed in a form fused with another polypeptide or peptide.
- a His-tag expression system Novagen
- a system Sigma
- GST fusion protein purification system Amersham Pharmacia
- MagneHis Protein Protein Purification System Promega
- GST transferase
- the target polypeptide is specifically purified using a nickel affinity column (GE Healthcare Bioscience) after being expressed as a fusion protein with oligohistidine as in the examples of the present invention. .
- Various peptides in the region that do not contain the homologous amino acid sequence between A.pg-A type bacteria and C type bacteria thus obtained are used to detect chicken infectious coryza vaccine antibodies and serological diagnosis of A.pg infected chickens. It is used for the antibody measurement for performing. Specifically, antibody measurement methods such as ELISA, Western blot, and dot blot are applied. When a large number of specimens are handled, an ELISA method using a microplate method in which a peptide is immobilized is preferable.
- a peptide consisting of a non-homologous region in the amino acid sequence encoded by the A.pg-1.3 gene and a part thereof can be used.
- an epitope recognized by an antibody can be formed with about 6 to 10 amino acids.
- a peptide which is a part of a non-homologous region and has a continuous amino acid sequence of 6 amino acids or more can be used in the present invention.
- the polypeptide encoded by A ⁇ 6b-2 # (P-A ⁇ 6b-2 #), the polypeptide encoded by C ⁇ 6b-1b (P-C ⁇ 6b-1b) and the polypeptide encoded by A ⁇ 7b-1b ( P-A ⁇ 7b-1b), and a part of the peptide consisting of a heterologous region in the amino acid sequence encoded by the A.pg-1.3 gene containing them are used.
- a mutant peptide obtained by adding an amino acid mutation to a part of these peptides can also be used as long as the sensitivity is not lowered and the nonspecific reaction is increased so as to hinder antibody detection.
- These peptides can be used in various combinations of two or more peptides according to the purpose.
- a single peptide or a mixture of peptides derived from A.pg-A bacteria or peptides derived from A.pg-C bacteria are preferably used independently.
- the immune serum after vaccine administration is a mixture of the above peptide and adjuvant, usually administered subcutaneously, intradermally, intraperitoneally, etc. of appropriate animals 1 to 3 times at intervals of 2 to 4 weeks, and then collected blood is collected. It can be obtained by centrifugation (14,000 rpm, 5 minutes).
- adjuvant Freund's complete adjuvant, Freund's incomplete adjuvant, aluminum hydroxide (for example, ImjectAlum (Pierce)) and the like are used.
- Sera from animals infected with Abibacterium paragalinarum can also be obtained by centrifuging blood.
- ELISA is performed by various methods, but any method may be used.
- a specimen immunoglobulin serum or A.pg-infected serum
- an anti-chicken antibody labeled as a secondary antibody is added.
- the sample and labeled anti-peptide (solid phase antigen) antibody are added simultaneously or separately to the microplate on which the peptide is immobilized, or the anti-peptide antibody is not labeled.
- ELISA using a competitive method in which a labeled secondary antibody against an anti-peptide antibody is added can be performed.
- Peptide immobilization on a microplate is usually performed by leaving the antigen in an amount of 1 to 10 ⁇ g / ml and leaving it at room temperature (around 25 ° C) for 30 minutes to 2 hours or at a low temperature (around 4 ° C) for 12 to 24 hours.
- blocking reagents for suppressing non-specific reactions include Block Ace (Snow Brand), ELISA blocking reagent (Roche Diagnostics), bovine serum albumin solution, skim milk solution, etc. That's fine.
- PBS, TBS, or those containing polysorbate (Tween 20) or preservative (sodium azide), etc. are used for washing after each reaction, and 2-3 mol of sulfuric acid is used for stopping the reaction.
- HRP As the secondary antibody, HRP, fluorescent labeling, RI, anti-chicken IgG monoclonal antibody labeled by biotinylation, such as anti-chicken IgG-HRP (Betchel), etc. are commercially available, and these may be used.
- biotinylation such as anti-chicken IgG-HRP (Betchel), etc.
- OPD orthophenylenediamine
- TMBZ 3,3 ′, 5,5′-tetramethylbenzidine
- an ELISA method using a two-antibody sandwich in which an antibody against a peptide is immobilized on a microplate and the peptide is bound to this antibody may be used.
- the antibody against the peptide can be either a polyclonal antibody or a monoclonal antibody.
- the polyclonal antibody is obtained by the same method as the above immune serum. Examples of animals used for immunization include chickens, rats, guinea pigs, hamsters, dogs and monkeys.
- Monoclonal antibodies can be obtained by collecting antibody-producing cells such as spleen cells or lymphocytes from animals immunized with A. pg cells or polypeptides, and using the method of Milstein et al.
- the established method for measuring anti-A.pg antibodies by ELISA is used for detection of vaccine antibodies or antibodies induced by A.pg infection.
- the present invention will be described in more detail with reference to examples. However, the present invention is not limited to the following examples.
- A.pg-1.3 gene and DNA fragment in the region A.pg-A type 221 and A.pg-C type 53-47 genomic DNA libraries were prepared by the method of Tokunaga et al. 84969). Briefly, chromosomal DNA is extracted from bacterial cells collected by centrifugation (8,000 rpm, 20 minutes) using a Sepagene kit (Sanko Junyaku), digested with the restriction enzyme Sau3AI, and a DNA library is prepared. did. Using the DNA fragment of this DNA library as a template (template), LA Taq (Takara Bio Inc.) was used to amplify a fragment comprising a part of the A.pg-1.3 gene by PCR according to the attached protocol.
- FIG. 1 shows the positional relationship of each DNA fragment.
- Table 1 shows the amplification of each DNA fragment and the PCR primers used for it. A restriction enzyme recognition sequence was added to each primer.
- Example 1 Expression of each DNA fragment
- Each DNA fragment obtained in Example 1 was digested with an appropriate restriction enzyme, separated by 0.8% agarose electrophoresis, and then the amplified fragment was eluted using a Quantum Prep Freeze N Squeeze DNA Gel Extraction Spin Co kit. It was collected. The obtained fragment was previously digested with the same restriction enzyme and ligated to the plasmid pQE30 (Qiagen: 6 His-tag sequences exist immediately under the start codon) or pET22b, which was dephosphorylated at the 5 ′ end, This was used to transform E. coli strain JM109. Further, E.
- coli containing the amplified fragment was cultured overnight in an ampicillin-containing circle glow medium (Funakoshi Co., Ltd.), and the next day IPTG was added to a final concentration of 1 mM and further cultured for 2.5 hours. After centrifugation (10,000 rpm, 5 minutes), the supernatant is discarded, and the sediment is 1/10 volume of Lysis Buffer A (8 M urea, 100 mM NaH 2 PO 4 , 10 mM Tris, 10 mM Imidazole, pH 8.0). And the cells were dissolved. After centrifugation (15,000 rpm, 15 minutes), the cell lysate supernatant was recovered.
- Lysis Buffer A 8 M urea, 100 mM NaH 2 PO 4 , 10 mM Tris, 10 mM Imidazole, pH 8.0.
- FIG. 2 shows the migration patterns of the expression products of A ⁇ 6b-1b and C ⁇ 6b-1b used as ELISA antigens in each of the A-type and C-type fragments.
- Polypeptide P-A ⁇ 5-1 obtained in Example 2 was diluted with PBS to 10 ⁇ g / dose, and aluminum hydroxide gel was added to a final concentration of 20%.
- Aluminum hydroxide gel was added to a final concentration of 20%.
- Other polypeptides P-A ⁇ 3-0, P-A ⁇ 5-0, P-C ⁇ 5-1 and P-C ⁇ 6-0 were diluted with PBS to 10 ⁇ g / dose and then emulsified with oil adjuvant.
- reaction solution After adsorption at room temperature for 1 hour, the reaction solution is discarded and 200 ⁇ L of PBS-T (8.1 mM disodium hydrogen phosphate, 1.5 mM dihydrogen phosphate, 137 mM sodium chloride, 2.7 mM potassium chloride, 0.05% Tween 20) is used. After washing, 200 ⁇ L of 5% skim milk-added PBS-T was added for blocking. The blocking solution was discarded, and serum was diluted 50 to 100 times with PBS-T supplemented with 1% skim milk, and 100 ⁇ L was added to each well, followed by reaction at room temperature for 1 hour.
- PBS-T 8.1 mM disodium hydrogen phosphate, 1.5 mM dihydrogen phosphate, 137 mM sodium chloride, 2.7 mM potassium chloride, 0.05% Tween 20
- a polypeptide (P-A ⁇ 6b-1b) containing a homologous amino acid sequence of 30 amino acids that match (see FIG. 3) is a polypeptide containing region 2 (P-A ⁇ 3-0, P-A ⁇ 5-1, P-A ⁇ 5). -0, P-C ⁇ 5-1, and P-C ⁇ 6-0) responded to any of the sera immunized.
- polypeptides (P-A ⁇ 6b-2 #, P-A ⁇ 7b-1b and P-C ⁇ 6b-1b) that did not contain the homologous amino acid sequence reacted with each other in a fungus-specific manner.
- Polypeptides P-A ⁇ 6b-2 # and P-A ⁇ 7b-1b also bound to A. pg-A-type infected sera.
- oil adjuvant vaccines oilbacks 7, Institute for Chemical and Serum Therapy
- inactivated cells and A.pg antigens of oilbacks 7 (types A and C)
- the same composition vaccine was prepared by adding the polypeptides A ⁇ 5-1 and C ⁇ 5-1 obtained in Example 2 instead of the inactivated cells of the mold and injected once subcutaneously into the neck of a 5-week-old SPF chicken .
- commercially available vaccines are also administered diluted 1/100 and 1 / 1,000, and polypeptides contain type A and type C mixed polypeptides diluted to 3,0.3 and 0.03 ⁇ g / feather respectively. The vaccine was administered.
- the bacterial solution of A.pg-A type 211 strain (1.5 x 10 9 CFU / mL) or A.pg-C type 53-47 (5.0 x 10 9 CFU / mL) 0.2 mL was administered intranasally and clinical symptoms such as facial swelling, nasal discharge and lacrimation were observed for 1 week.
- the obtained serum was subjected to ELISA measurement by the following method.
- Polypeptides P-A ⁇ 6b-2 # and P-C ⁇ 6b-1b obtained in Example 2 were diluted with 50 mM bicarbonate buffer so as to be 1.0 ⁇ g / mL, and 50 ⁇ L each was put into a 96-well plate and immobilized. After adsorption overnight at 4 ° C, the reaction solution is discarded, and 300 ⁇ L of PBS-T (8.1 mM disodium hydrogen phosphate, 1.5 mM dihydrogen phosphate, 137 mM sodium chloride, 2.7 mM potassium chloride, 0.1% Tween 20) is used.
- the plate was washed 3 times with PBS-T, 100 ⁇ L of a chromogenic substrate solution (TMB + substrate-chromogen; DAKO) was added, and the mixture was reacted at room temperature for 15 minutes. Color development was stopped by adding 100 ⁇ L of 3M sulfuric acid. The wavelength of 450 nm was measured with a 96 well plate reader (manufactured by Nippon Molecular Device Co., Ltd.).
- the detection method of the present invention is used for examining the immune status of chickens immunized with a vaccine composed of a polypeptide containing the amino acid sequence used in the present invention.
- the detection method of the present invention is used for research on the onset mechanism and epidemiology by measuring the serum of chickens that have developed chicken infectious coryza due to A.pg infection.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
ペプチドA:
配列番号1で示されるアミノ酸配列の一部であって、6アミノ酸以上のペプチド鎖からなり、且つ配列番号1で示されるアミノ酸配列の243~273番目のアミノ酸配列を含有しないペプチド。
ペプチドB:
配列番号2で示されるアミノ酸配列の一部であって、6アミノ酸以上のペプチド鎖からなり、且つ配列番号2で示されるアミノ酸配列の38~68番目のアミノ酸配列を含有しないペプチド。
(2)ペプチドAまたはBが、10アミノ酸以上のペプチド鎖であることを特徴とする上記1記載の検出方法。
(3)ペプチドAまたはBが、20アミノ酸以上のペプチド鎖であることを特徴とする上記1記載の検出方法。
(4)ペプチドAまたはBが、下記のペプチド鎖であることを特徴とする、上記1記載の検出方法。
ペプチドA:
配列番号1で示されるアミノ酸配列の一部であって、配列番号1で示されるアミノ酸配列の8~236番目のアミノ酸配列を含有し、且つ配列番号1で示されるアミノ酸配列の243~273番目のアミノ酸配列を含有しないペプチド。
ペプチドB:
配列番号2で示されるアミノ酸配列の一部であって、配列番号2で示されるアミノ酸配列の69~452番目のアミノ酸配列を含有し、且つ配列番号2で示されるアミノ酸配列の38~68番目のアミノ酸配列を含有しないペプチド。
(5)ペプチドAまたはBが、下記のペプチド鎖であることを特徴とする、上記1記載の検出方法。
ペプチドA:
配列番号1で示されるアミノ酸配列の8~236番目のアミノ酸配列からなるペプチド。
ペプチドB:
配列番号2で示されるアミノ酸配列の69~452番目のアミノ酸配列からなるペプチド。
(6)ペプチドAが、下記のペプチド鎖であることを特徴とする、上記4記載の検出方法。
ペプチドA:
配列番号1で示されるアミノ酸配列の一部であって、配列番号1で示されるアミノ酸配列の274~445番目のアミノ酸配列を含有し、且つ配列番号1で示されるアミノ酸配列の243~273番目のアミノ酸配列を含有しないペプチド。
(7)ペプチドAが、下記のペプチド鎖であることを特徴とする、上記5記載の検出方法。
ペプチドA:
配列番号1で示されるアミノ酸配列の274~445番目のアミノ酸配列からなるペプチド。
(8)ペプチドAまたはBが、1もしくは数個のアミノ酸残基が欠失、付加、あるいは置換されたアミノ酸配列を有するペプチドであることを特徴とする、上記1ないし7の何れか一つに記載の検出方法。
(9)抗体測定法が、ELISA法、ウェスタンブロット法およびドットブロット法からなる群より選ばれることを特徴とする、上記1ないし8記載の検出方法。
(10)検体が、アビバクテリウム・パラガリナラム感染鶏血清またはアビバクテリウム・パラガリナラムワクチン投与鶏血清であることを特徴とする、上記1ないし9の何れか一つに記載の検出方法。
(11)下記のペプチドAまたはBの少なくとも一つを抗原として用いることを特徴とする、アビバクテリウム・パラガリナラム抗体測定キット。
ペプチドA:
配列番号1で示されるアミノ酸配列の一部であって、6アミノ酸以上のペプチド鎖からなり、且つ配列番号1で示されるアミノ酸配列の243~273番目のアミノ酸配列を含有しないペプチド。
ペプチドB:
配列番号2で示されるアミノ酸配列の一部であって、6アミノ酸以上のペプチド鎖からなり、且つ配列番号2で示されるアミノ酸配列の38~68番目のアミノ酸配列を含有しないペプチド。
(12)ペプチドAまたはBが、10アミノ酸以上のペプチド鎖であることを特徴とする上記11記載の抗体測定キット。
(13)ペプチドAまたはBが、20アミノ酸以上のペプチド鎖であることを特徴とする上記11記載の抗体測定キット。
(14)ペプチドAまたはBが、下記のペプチド鎖であることを特徴とする、上記11記載の抗体測定キット。
ペプチドA:
配列番号1で示されるアミノ酸配列の一部であって、配列番号1で示されるアミノ酸配列の8~236番目のアミノ酸配列を含有し、且つ配列番号1で示されるアミノ酸配列の243~273番目のアミノ酸配列を含有しないペプチド。
ペプチドB:
配列番号2で示されるアミノ酸配列の一部であって、配列番号2で示されるアミノ酸配列の69~452番目のアミノ酸配列を含有し、且つ配列番号2で示されるアミノ酸配列の38~68番目のアミノ酸配列を含有しないペプチド。
(15)ペプチドAまたはBが、下記のペプチド鎖であることを特徴とする、上記11記載の抗体測定キット。
ペプチドA:
配列番号1で示されるアミノ酸配列の8~236番目のアミノ酸配列からなるペプチド。
ペプチドB:
配列番号2で示されるアミノ酸配列の69~452番目のアミノ酸配列からなるペプチド。
(16)ペプチドAが、下記のペプチド鎖であることを特徴とする、上記14記載の抗体測定キット。
ペプチドA:
配列番号1で示されるアミノ酸配列の一部であって、配列番号1で示されるアミノ酸配列の274~445番目のアミノ酸配列を含有し、且つ配列番号1で示されるアミノ酸配列の243~273番目のアミノ酸配列を含有しないペプチド。
(17)ペプチドAが、下記のペプチド鎖であることを特徴とする、上記15記載の抗体測定キット。
ペプチドA:
配列番号1で示されるアミノ酸配列の274~445番目のアミノ酸配列からなるペプチド。
(18)ペプチドAまたはBが、1もしくは数個のアミノ酸残基が欠失、付加、あるいは置換されたアミノ酸配列を有するペプチドであることを特徴とする、上記11ないし17の何れか一に記載の抗体測定キット。
(19)抗体測定法が、ELISA法、ウェスタンブロット法およびドットブロット法からなる群より選ばれることを特徴とする、上記11ないし18の何れか一に記載の抗体測定キット。
(20)検体が、アビバクテリウム・パラガリナラム感染鶏血清またはアビバクテリウム・パラガリナラムワクチン投与鶏血清であることを特徴とする、上記11ないし19の何れか一に記載の抗体測定キット。
アビバクテリウム・パラガリナラム感染動物の血清も、同様に血液を遠心分離することにより得られる。
A.pg-A型菌221株およびA.pg-C型菌53-47株のゲノムDNAライブラリーを徳永らの方法(特開平10-84969)により調製した。簡単には、遠心分離(8,000rpm、20分間)により回収された菌体からからセパジーンキット(三光純薬)を用いて染色体DNAを抽出し、制限酵素Sau3AIで消化し、DNAライブラリーを調製した。このDNAライブラリーのDNA断片を鋳型(テンプレート)として、LA Taq(タカラバイオ株式会社)を用いて、添付のプロトコールに従い、PCR法によりA.pg-1.3遺伝子の一部からなる断片を増幅した。PCR反応は、LA PCRキットver2(宝酒造製)を用い、96℃で1分反応の後、96℃で40秒間、56℃で60秒間、72℃で120秒間の反応を30サイクル、その後72℃で10分間の反応を行った。図1に、各DNA断片の位置関係を示す。また、各DNA断片の増幅とそれに用いたPCRプライマーを表1に示す。各プライマーには、制限酵素認識配列を付加した。
実施例1で得た各DNA断片を適当な制限酵素で消化し、0.8%アガロース電気泳動で分離後、増幅フラグメントをQuantum Prep Freeze N Squeeze DNA Gel Extraction Spin Coキットを用い溶出、回収した。得られた断片を、予め、同じ制限酵素で消化し、5'末端を脱リン酸化したプラスミドpQE30(キアゲン社製:6個のHis-tag配列が開始コドン直下に存在)またはpET22bに連結し、これを用いて大腸菌JM109株を形質転換した。更に増幅フラグメントを含む大腸菌を、アンピシリン含有サークルグロー培地(フナコシ株式会社)で1夜培養し、翌日IPTGを終濃度1mMとなるように加え、更に2.5時間培養した。遠心分離(10,000rpm、5分間)後、上清を捨て、沈さを培養液の1/10量のLysis Buffer A(8M尿素, 100mM NaH2PO4, 10mM Tris, 10mM Imidazole, pH8.0)に懸濁し、菌体を溶解した。遠心分離(15,000rpm、15分)後、セルライセイト上清を回収した。回収したセルライセイト上清をNi-NTAアガロースゲル1mLと混合し、ゲルに吸着させた後、ボトム栓付きカラムに充填した。カラムを洗浄後、溶出液(8M尿素, 100mM NaH2PO4, 10mM Tris, 100mM Imidazole, pH8.0)で溶出画分を回収し、ドデシル硫酸ナトリウムポリアクリルアミド電気泳動(SDS-PAGE)を行った。A型、C型、それぞれの断片中、ELISA抗原として用いたAΔ6b-1bおよびCΔ6b-1bの発現産物の泳動パターンを図2に示す。
実施例2で得たポリペプチドP-AΔ5-1を10μg/doseとなるようにPBSで希釈し、更に水酸化アルミニウムゲルを終濃度20%になるように加えたものを、5週齢SPF鶏の頸部皮下に3週間隔で2回免疫した。他のポリペプチドP-AΔ3-0, P-AΔ5-0, P-CΔ5-1およびP-CΔ6-0については、10μg/doseとなるようにPBSで希釈した後、オイルアジュバントと乳化したものを調製(1ドーズ(0.5mL)あたり、抗原0.01g、ホルマリン0.001mL以下、ポリソルベート80 0.01mL、セスキオレイン酸ソルビタン0.04mL、軽質流動パラフィン0.36mL、リン酸緩衝液残量)し、5週齢SPF鶏の頸部皮下に1回投与した。9~11週齢時に採血し、各ポリペプチドに対する免疫血清を得た。
実施例2で得たポリペプチドP-AΔ6b-1b, P-AΔ6b-2♯, P-AΔ7b-1bおよびP-CΔ6b-1bを1.0~2.5μg/mLとなるように50mM重炭酸バッファーで希釈し、96 wellプレートに100μLずつ入れ固相化した。室温で1時間吸着後、反応液を捨て、200μLのPBS-T(8.1mMリン酸水素2ナトリウム、1.5mMリン酸2水素1カリウム、137mM塩化ナトリウム、2.7mM塩化カリウム、0.05%ツイーン20)で洗浄後、200μLの5%スキムミルク加 PBS-Tを入れブロッキングした。ブロッキング液を捨て、血清を1%スキムミルク加 PBS-Tで50~100倍希釈し各wellに100μLずつ添加し、室温で1時間反応させた。反応液を除去後、PBS-Tで3回洗浄し、抗鶏IgG-HRP標識抗体を1%スキムミルク加 PBS-Tで10,000~20,000倍希釈し100μLずつ添加した。暗所で室温、1時間反応させた。反応液を除去後、PBS-Tで3回洗浄し、発色基質液(100mMクエン酸、200mMリン酸水素2ナトリウム、0.004%オルトフェニレンジアミン、過酸化水素)を100μLずつ添加し、室温で30分間反応させた。3M硫酸を100μLずつ添加し、発色を停止させた。96wellプレートリーダー(日本モレキューラーデバイス社製)で492nmの波長を測定した。その結果を表2に示す。
不活化菌体を用いた市販のオイルアジュバントワクチン(オイルバックス7、財団法人化学及血清療法研究所)およびオイルバックス7のA.pg抗原(A型菌およびC型菌の不活化菌体)の替わりに実施例2で得たポリペプチドAΔ5-1およびCΔ5-1を加えた同組成ワクチンを調製し、5週齢SPF鶏の頸部皮下に1回注射した。市販ワクチンは1ドースのほかに1/100および1/1,000に希釈したものも投与し、ポリペプチドはそれぞれが 3, 0.3および0.03μg/羽となるように希釈したA型C型混合ポリペプチド含有ワクチンを投与した。9週齢時に採血後、A.pg-A型菌211株(1.5 x 109 CFU/mL)またはA.pg-C型菌53-47株(5.0 x 109CFU/mL)の菌液0.2mLを鼻腔内投与し、1週間、顔面腫脹、鼻汁漏出、流涙などの臨床症状を観察した。
Claims (20)
- 下記のペプチドAまたはBの少なくとも一つの抗原と検体を反応させる抗体測定法からなることを特徴とする、アビバクテリウム・パラガリナラム抗体の検出方法。
ペプチドA:
配列番号1で示されるアミノ酸配列の一部であって、6アミノ酸以上のペプチド鎖からなり、且つ配列番号1で示されるアミノ酸配列の243~273番目のアミノ酸配列を含有しないペプチド。
ペプチドB:
配列番号2で示されるアミノ酸配列の一部であって、6アミノ酸以上のペプチド鎖からなり、且つ配列番号2で示されるアミノ酸配列の38~68番目のアミノ酸配列を含有しないペプチド。 - ペプチドAまたはBが、10アミノ酸以上のペプチド鎖であることを特徴とする請求項1記載の検出方法。
- ペプチドAまたはBが、20アミノ酸以上のペプチド鎖であることを特徴とする請求項1記載の検出方法。
- ペプチドAまたはBが、下記のペプチド鎖であることを特徴とする、請求項1記載の検出方法。
ペプチドA:
配列番号1で示されるアミノ酸配列の一部であって、配列番号1で示されるアミノ酸配列の8~236番目のアミノ酸配列を含有し、且つ配列番号1で示されるアミノ酸配列の243~273番目のアミノ酸配列を含有しないペプチド。
ペプチドB:
配列番号2で示されるアミノ酸配列の一部であって、配列番号2で示されるアミノ酸配列の69~452番目のアミノ酸配列を含有し、且つ配列番号2で示されるアミノ酸配列の38~68番目のアミノ酸配列を含有しないペプチド。 - ペプチドAまたはBが、下記のペプチド鎖であることを特徴とする、請求項1記載の検出方法。
ペプチドA:
配列番号1で示されるアミノ酸配列の8~236番目のアミノ酸配列からなるペプチド。
ペプチドB:
配列番号2で示されるアミノ酸配列の69~452番目のアミノ酸配列からなるペプチド。 - ペプチドAが、下記のペプチド鎖であることを特徴とする、請求項4記載の検出方法。
ペプチドA:
配列番号1で示されるアミノ酸配列の一部であって、配列番号1で示されるアミノ酸配列の274~445番目のアミノ酸配列を含有し、且つ配列番号1で示されるアミノ酸配列の243~273番目のアミノ酸配列を含有しないペプチド。 - ペプチドAが、下記のペプチド鎖であることを特徴とする、請求項5記載の検出方法。
ペプチドA:
配列番号1で示されるアミノ酸配列の274~445番目のアミノ酸配列からなるペプチド。 - ペプチドAまたはBが、1もしくは数個のアミノ酸残基が欠失、付加、あるいは置換されたアミノ酸配列を有するペプチドであることを特徴とする、請求項1ないし7の何れか一項記載の検出方法。
- 抗体測定法が、ELISA法、ウェスタンブロット法およびドットブロット法からなる群より選ばれることを特徴とする、請求項1ないし8記載の検出方法。
- 検体が、アビバクテリウム・パラガリナラム感染鶏血清またはアビバクテリウム・パラガリナラムワクチン投与鶏血清であることを特徴とする、請求項1ないし9の何れか一項に記載の検出方法。
- 下記のペプチドAまたはBの少なくとも一つを抗原として用いることを特徴とする、アビバクテリウム・パラガリナラム抗体測定キット。
ペプチドA:
配列番号1で示されるアミノ酸配列の一部であって、6アミノ酸以上のペプチド鎖からなり、且つ配列番号1で示されるアミノ酸配列の243~273番目のアミノ酸配列を含有しないペプチド。
ペプチドB:
配列番号2で示されるアミノ酸配列の一部であって、6アミノ酸以上のペプチド鎖からなり、且つ配列番号2で示されるアミノ酸配列の38~68番目のアミノ酸配列を含有しないペプチド。 - ペプチドAまたはBが、10アミノ酸以上のペプチド鎖であることを特徴とする請求項11記載の抗体測定キット。
- ペプチドAまたはBが、20アミノ酸以上のペプチド鎖であることを特徴とする請求項11記載の抗体測定キット。
- ペプチドAまたはBが、下記のペプチド鎖であることを特徴とする、請求項11記載の抗体測定キット。
ペプチドA:
配列番号1で示されるアミノ酸配列の一部であって、配列番号1で示されるアミノ酸配列の8~236番目のアミノ酸配列を含有し、且つ配列番号1で示されるアミノ酸配列の243~273番目のアミノ酸配列を含有しないペプチド。
ペプチドB:
配列番号2で示されるアミノ酸配列の一部であって、配列番号2で示されるアミノ酸配列の69~452番目のアミノ酸配列を含有し、且つ配列番号2で示されるアミノ酸配列の38~68番目のアミノ酸配列を含有しないペプチド。 - ペプチドAまたはBが、下記のペプチド鎖であることを特徴とする、請求項11記載の抗体測定キット。
ペプチドA:
配列番号1で示されるアミノ酸配列の8~236番目のアミノ酸配列からなるペプチド。
ペプチドB:
配列番号2で示されるアミノ酸配列の69~452番目のアミノ酸配列からなるペプチド。 - ペプチドAが、下記のペプチド鎖であることを特徴とする、請求項14記載の抗体測定キット。
ペプチドA:
配列番号1で示されるアミノ酸配列の一部であって、配列番号1で示されるアミノ酸配列の274~445番目のアミノ酸配列を含有し、且つ配列番号1で示されるアミノ酸配列の243~273番目のアミノ酸配列を含有しないペプチド。 - ペプチドAが、下記のペプチド鎖であることを特徴とする、請求項15記載の抗体測定キット。
ペプチドA:
配列番号1で示されるアミノ酸配列の274~445番目のアミノ酸配列からなるペプチド。 - ペプチドAまたはBが、1もしくは数個のアミノ酸残基が欠失、付加、あるいは置換されたアミノ酸配列を有するペプチドであることを特徴とする、請求項11ないし17の何れか一項に記載の抗体測定キット。
- 抗体測定法が、ELISA法、ウェスタンブロット法およびドットブロット法からなる群より選ばれることを特徴とする、請求項11ないし18の何れか一項に記載の抗体測定キット。
- 検体が、アビバクテリウム・パラガリナラム感染鶏血清またはアビバクテリウム・パラガリナラムワクチン投与鶏血清であることを特徴とする、請求項11ないし19の何れか一項に記載の抗体測定キット。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010008687A MX2010008687A (es) | 2008-02-08 | 2009-02-06 | Metodo y kit para detectar anticuerpos a avibacterium paragallinarum. |
CN200980113170.8A CN102007414B (zh) | 2008-02-08 | 2009-02-06 | 副鸡禽杆菌抗体的检测方法和试剂盒 |
US12/866,793 US8298778B2 (en) | 2008-02-08 | 2009-02-06 | Method and kit for detecting antibody to avibacterium paragallinarum |
KR1020107019926A KR101528169B1 (ko) | 2008-02-08 | 2009-02-06 | 아비박테리움 파라갈리나룸 항체의 검출방법 및 키트 |
JP2009552548A JP5379698B2 (ja) | 2008-02-08 | 2009-02-06 | アビバクテリウム・パラガリナラム抗体の検出方法およびキット |
EP09709287.8A EP2251693B1 (en) | 2008-02-08 | 2009-02-06 | Method and kit for detection of anti-avibacterium paragallinarum antibody |
ES09709287.8T ES2437148T3 (es) | 2008-02-08 | 2009-02-06 | Método y kit para detección de anticuerpo anti-Avibacterium paragallinarum |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008029589 | 2008-02-08 | ||
JP2008-029589 | 2008-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009099204A1 true WO2009099204A1 (ja) | 2009-08-13 |
Family
ID=40952272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/052091 WO2009099204A1 (ja) | 2008-02-08 | 2009-02-06 | アビバクテリウム・パラガリナラム抗体の検出方法およびキット |
Country Status (8)
Country | Link |
---|---|
US (1) | US8298778B2 (ja) |
EP (1) | EP2251693B1 (ja) |
JP (1) | JP5379698B2 (ja) |
KR (1) | KR101528169B1 (ja) |
CN (1) | CN102007414B (ja) |
ES (1) | ES2437148T3 (ja) |
MX (1) | MX2010008687A (ja) |
WO (1) | WO2009099204A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110540579A (zh) * | 2018-05-29 | 2019-12-06 | 普莱柯生物工程股份有限公司 | 一种副鸡禽杆菌抗原蛋白、含有副鸡禽杆菌抗原的疫苗组合物、及其制备方法和应用 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105949287B (zh) * | 2016-06-29 | 2019-05-24 | 北京市农林科学院 | 一种a型副鸡禽杆菌免疫保护性抗原及其应用 |
CN107266538B (zh) * | 2016-07-28 | 2020-09-11 | 北京市农林科学院 | 鸡传染性鼻炎亚单位疫苗及其制备方法 |
CN107219364A (zh) * | 2017-04-14 | 2017-09-29 | 杨凌职业技术学院 | 检测a型副鸡嗜血杆菌抗体的间接elisa试剂盒及其检测方法及其应用 |
CN107402301A (zh) * | 2017-08-06 | 2017-11-28 | 潘金文 | 一种家禽病原体高通量检测芯片及其应用 |
PE20191840A1 (es) * | 2018-06-19 | 2019-12-31 | Farm Veterinarios S A C | Kit diagnostico diferencial y rapido para deteccion de la coriza infecciosa y el sindrome de cabeza hinchada en la industria avicola |
CN114184791A (zh) * | 2020-09-15 | 2022-03-15 | 北京市农林科学院 | 一种检测副鸡禽杆菌外膜蛋白抗体的胶体金试纸及其制备方法与应用 |
CN114236128B (zh) * | 2021-11-30 | 2022-07-29 | 中国农业科学院兰州兽医研究所 | 一种检测猪急性腹泻综合征冠状病毒n蛋白抗体的阻断elisa试剂盒 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS64467A (en) * | 1987-11-20 | 1989-01-05 | Kitasato Inst:The | Measuring system using hemagglutinin of agglutinin deficient strain to fresh red blood cells of haemophilus paragallinarum |
WO1998012331A1 (fr) | 1996-09-19 | 1998-03-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Nouveau polypeptidetire de hemophilus paragallinarum et son procede de production |
JP2002154983A (ja) * | 2000-11-20 | 2002-05-28 | Shionogi & Co Ltd | ヘモフィルス・パラガリナルムワクチン |
JP2005218414A (ja) | 2004-02-09 | 2005-08-18 | Biseibutsu Kagaku Kenkyusho:Kk | ヘモフィルス・パラガリナラムa型菌由来の感染防御抗原である組み換え蛋白 |
-
2009
- 2009-02-06 MX MX2010008687A patent/MX2010008687A/es active IP Right Grant
- 2009-02-06 KR KR1020107019926A patent/KR101528169B1/ko active IP Right Grant
- 2009-02-06 EP EP09709287.8A patent/EP2251693B1/en not_active Not-in-force
- 2009-02-06 US US12/866,793 patent/US8298778B2/en active Active
- 2009-02-06 CN CN200980113170.8A patent/CN102007414B/zh not_active Expired - Fee Related
- 2009-02-06 JP JP2009552548A patent/JP5379698B2/ja active Active
- 2009-02-06 ES ES09709287.8T patent/ES2437148T3/es active Active
- 2009-02-06 WO PCT/JP2009/052091 patent/WO2009099204A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS64467A (en) * | 1987-11-20 | 1989-01-05 | Kitasato Inst:The | Measuring system using hemagglutinin of agglutinin deficient strain to fresh red blood cells of haemophilus paragallinarum |
WO1998012331A1 (fr) | 1996-09-19 | 1998-03-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Nouveau polypeptidetire de hemophilus paragallinarum et son procede de production |
JPH1084969A (ja) | 1996-09-19 | 1998-04-07 | Chemo Sero Therapeut Res Inst | ヘモフィルス・パラガリナルム由来新規ポリペプチド及びその製法 |
JP2002154983A (ja) * | 2000-11-20 | 2002-05-28 | Shionogi & Co Ltd | ヘモフィルス・パラガリナルムワクチン |
JP2005218414A (ja) | 2004-02-09 | 2005-08-18 | Biseibutsu Kagaku Kenkyusho:Kk | ヘモフィルス・パラガリナラムa型菌由来の感染防御抗原である組み換え蛋白 |
Non-Patent Citations (10)
Title |
---|
AM. J. VET. RES., vol. 23, 1962, pages 85 - 95 |
AM. J. VET. RES., vol. 41, 1980, pages 1901 - 1904 |
AM. J. VET. RES., vol. 41, 1980, pages 757 - 760 |
AVIAN DIS., vol. 15, 1971, pages 109 - 117 |
INT. ASS. BIO., vol. 35, 2007, pages 317 - 320 |
JPN. J. VET. SCI., vol. 40, 1978, pages 645 - 652 |
MILSTEIN ET AL., METHOD ENZYMOL., vol. 73, 1981, pages 3 - 46 |
NORO ET AL., 143RD MEETING OF THE JAPANESE SOCIETY OF VETERINARY SCIENCE, 3 April 2007 (2007-04-03) |
NORO T. ET AL.: "Haemophilus paragallinarum A-gata Kin ni Taishite Tsuyoi HI Kassei o Yusuru Tan Clone Kotai ga Ninshiki suru Kogen o Code suru Idenshi Ryoiki no Kento", NIPPON JUI GAKKAI GAKUJUTSU SHUKAI KOEN YOSHISHU, vol. 139, 2005, pages 212, XP008147773 * |
TOKUNAGA E. ET AL.: "Haemophilus paragallinarum A- gata Kin no Kansen Bogyo Kogen Idenshi no Cloning", NIPPON JUI GAKKAI GAKUJUTSU SHUKAI KOEN YOSHISHU, vol. 126, 1998, pages 229 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110540579A (zh) * | 2018-05-29 | 2019-12-06 | 普莱柯生物工程股份有限公司 | 一种副鸡禽杆菌抗原蛋白、含有副鸡禽杆菌抗原的疫苗组合物、及其制备方法和应用 |
CN110540579B (zh) * | 2018-05-29 | 2022-09-06 | 普莱柯生物工程股份有限公司 | 一种副鸡禽杆菌抗原蛋白、含有副鸡禽杆菌抗原的疫苗组合物、及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
US20110201034A1 (en) | 2011-08-18 |
EP2251693B1 (en) | 2013-11-13 |
MX2010008687A (es) | 2011-02-22 |
US8298778B2 (en) | 2012-10-30 |
KR101528169B1 (ko) | 2015-06-11 |
EP2251693A1 (en) | 2010-11-17 |
CN102007414A (zh) | 2011-04-06 |
JPWO2009099204A1 (ja) | 2011-05-26 |
CN102007414B (zh) | 2015-06-17 |
EP2251693A4 (en) | 2011-04-20 |
KR20100134584A (ko) | 2010-12-23 |
ES2437148T3 (es) | 2014-01-09 |
JP5379698B2 (ja) | 2013-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5379698B2 (ja) | アビバクテリウム・パラガリナラム抗体の検出方法およびキット | |
US20090202528A1 (en) | Surface-Located Streptococcus Pneumoniae Polypeptides | |
US10035841B2 (en) | Monoclonal antibody against novel epitopes of foot-and-mouth disease virus protein 3ABC and uses thereof | |
AU2012298229B2 (en) | Improved vaccine diagnostics | |
WO2008119358A2 (en) | Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions | |
CN110642927A (zh) | 一种蛋白在制备预防化脓隐秘杆菌感染的药物中的应用 | |
KR20100139096A (ko) | 조성물, 방법 및 키트 | |
JPWO2006073133A1 (ja) | 新規タンナーゼ遺伝子およびそのタンパク質 | |
CA2571673A1 (en) | Novel methods of diagnosis of treatment of p. aeruginosa infection and reagents therefor | |
US20090068218A1 (en) | Antigens for Vaccination Against and Detection of Mycoplasma Suis | |
KR100862084B1 (ko) | 유행성이하선염 바이러스 핵단백질 및 이것의 용도 | |
KR20220114257A (ko) | PEDV 유래 재조합 스파이크 단백질을 포함하는 PEDV 특이 IgA 검출 키트 | |
WO2003013601A1 (en) | Toxin associated with sudden infant death syndrome, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980113170.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09709287 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009552548 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/008687 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12866793 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009709287 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107019926 Country of ref document: KR Kind code of ref document: A |